Patents/Assignees

Immunity Bio, Inc.

3 patents in portfolio

US11911459utility2024
Nant COVID Vaccine Cross Reactivity
0 cites
US11813292utility2023
Use of CD33CAR Modified High Affinity NK Cells (t-hank) to Reduce Myeloid-derived Suppressor Cells Suppressor Activity (or Reduce Negative Impact on NK Cell Activity)
0 cites
US11788059utility2023
Modified NK-92 Cells for Treating Cancer
0 cites